Vaxcyte
Prezzo: 47.46Società e modello di business
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Its core products include a pipeline of vaccine candidates targeting various pathogens, with a primary emphasis on pneumococcal disease. The company operates within the healthcare sector, primarily generating revenue through research and development activities and potential future product sales.
Profilo di investimento
The investment profile of Vaxcyte is more aligned with growth investors, given its focus on developing new vaccine technologies and the potential for significant future revenue from successful product launches. The stock may appeal to those with a medium to long-term investment horizon, as the company is still in the development phase. Liquidity is moderate, suitable for investors with basic to advanced experience in the biotech sector.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -6.89 Rischio
- Sorpresa EPS
- -29.7% peggio del previsto
- Volatilità 20g
- 3.1% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-03 02:49 | Mantieni | Vendi | scenario_deterioration |
| 2026-05-28 02:54 | Vendi | Mantieni | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-20 02:53 | Mantieni | Vendi | scenario_deterioration |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-02-25 19:27 | BTIG | Target alzato | — → 89 | 63.04 |
| 2025-11-19 10:23 | Leerink Partners | Target alzato | — → 77 | 49.53 |
Ancora nulla